

AMENDMENTIn the claims:

Please amend the claims to read as follows:

a<sup>1</sup> 6. (Amended) The composition of claim 1 wherein said amyloidogenic (poly)peptide self-assembles subsequent to release from said fusion protein.

8. (Amended) The composition of claim 1 wherein said (poly)peptide defined in (aa) is glutathione S-transferase (GST), intein, thioredoxin, dihydrofolate reductase (DHFR) or chymotrypsin inhibitor 2 (CI2) or a functional fragment or derivative thereof.

a<sup>2</sup> 9. (Amended) The composition of claim 1 wherein said nucleic acid is DNA.

10. (Amended) The composition of claim 1 wherein said vector is an expression vector or a gene targeting vector.

11. (Amended) The composition of claim 1 wherein said host is a bacterial, preferably an E coli, an animal-, preferably a mammalian, an insect-, a plant-, a fungal, preferably a yeast- and most preferably a Saccharomyces or Aspergillus cell, a Pichia pastoris cell, a transgenic animal or a transgenic plant.

13. (Amended) The composition of claim 1 wherein said antibody is a monoclonal antibody, polyclonal antibody, phage display antibody or a fragment or derivative thereof.

a<sup>3</sup> 14. (Amended) An in vitro method of producing amyloid aggregates comprising

- (a) at least partially cleaving the fusion protein comprised in the composition of claim 1 wherein the (poly)peptide that is released has the ability to self-assemble into amyloid-like fibrils or protein aggregates; or
- (b) inducing self-assembly into amyloid-like fibrils or protein aggregates by heating the fusion protein comprised in the composition of claim 1 or an amyloidogenic

a<sup>3</sup>  
cont

(poly)peptide that has the ability to self-assemble into amyloid-like fibrils or protein aggregates, by inducing a pH change in a solution comprising said fusion protein/(poly)peptide or by treating said fusion protein/(poly)peptide with a denaturing agent.

---

- a<sup>4</sup>
16. (Amended) A method of testing a prospective inhibitor of aggregate formation of a fusion protein as defined in the composition of claim 1 when enzymatically or chemically cleaved or a non-cleaved fusion amyloidogenic (poly)peptide as defined in claim 1 or an amyloidogenic non-fusion (poly) peptide comprising
- (a) incubating in the presence of a prospective inhibitor
  - (aa) said fusion protein in the presence or absence of a cleaving agent; or
  - (ab) said non-fusion poly(peptide); and
  - (b) assessing the formation of amyloid-like fibrils or protein aggregates.
- 

- a<sup>5</sup>
18. (Amended) A method for identifying an inhibitor of aggregate formation of a fusion protein as defined in claim 2 prior to or after proteolytic or chemical cleavage or of a non-fusion amyloidogenic (poly)peptide hat has the ability to self-assemble into amyloid-like fibrils or protein aggregates comprising
- (a) loading a surface or gel with said protein or an aggregate thereof;
  - (b) incubating said surface or gel with a prospective inhibitor; and
  - (c) assessing whether the presence of said prospective inhibitor avoids or reduces aggregate formation or further aggregate formation.
- 

Please additionally cancel claims 20-21.

---

#### REMARKS

In response to the Restriction Requirement, Applicants have elected to prosecute the claims of Group I and the species of a fusion protein with traverse. The traversal is made on the grounds that the fusion protein includes both elements aa and ab. The claim does not make sense